US/UK/Canada

Share

Contacts

  • Ulf Hannelius

    CEO


    Box 7349, SE-103 90 Stockholm
    +46 8 661 00 26
    +46 8 661 63 68
    https://www.diamyd.com

    • Links

    Quotes

    The collected genetic and immunological insights support the possibility that we may be able to truly individualize the treatment.
    Ulf Hannelius, CEO
    Our top strategic priority is to prepare for a marketing application for Diamyd®
    Ulf Hannelius, CEO
    Pick a time period -
    Tags ( Active)

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on November 30, 2023. The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2022/2023. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2022/2023. Anders Essen-Möller, Erik Nerpin, Maria-Teresa Essen-Möller, Torbjörn Bäckström, Mark A. Atkinson and Karin Hehenberger were re-elected to the Board. Karin Rosén, M.D, PhD, was elected as a new member of the Board.

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on December 1, 2022. Full information and documents regarding the Annual General Meeting's resolutions can be found on the Company's website, https://www.diamyd.com. All resolutions passed by the Annual General Meeting are in accordance with the proposals presented in the notice.The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2021/2022. The Annual General Meeting approved the Board's proposal that no dividend

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on December 2, 2021. The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2020/2021. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2020/2021. Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller, Torbjörn Bäckström and Mark A. Atkinson were re-elected to the Board. M.D, Ph.D Karin Hehenberger, founder and

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on November 26, 2020. The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2019/2020. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2019/2020. Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller, Torbjörn Bäckström and Mark A. Atkinson were re-elected to the Board. The Annual General Meeting approved

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on November 21, 2019. The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2018/2019. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2018/2019. Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller, Torbjörn Bäckström and Mark A. Atkinson were re-elected to the Board. The Annual General Meeting approved

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The Annual General Meeting of Diamyd Medical AB (publ) was held on November 30, 2017. The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the 2016/2017 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2016/2017 fiscal year. Erik Nerpin was re-elected as Chairman of the Board and Anders Essen-Möller, Maria-Teresa Essen-Möller and Torbjörn Bäckström were re-elected to the Board. The Annual General Meeting approved the proposed

    Bulletin from Annual General Meeting of Diamyd Medical AB

    The following items were addressed at the Annual General Meeting of Diamyd Medical AB (publ) held today: Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of the past year and summarized the most significant events that took place during the fiscal year and after year-end. The Company's income statement and balance sheet were adopted and the Board members and the Chief Executive Officer were discharged from liability for the 2013/2014 fiscal year. The Annual General Meeting approved the Board's proposal that no dividend be paid for the 2013/2014 fiscal year.

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media